1. Did the BOOG 2013–08, which examines the value of omission of the sentinel lymph node in cT1-2 breast cancer treated with BCT, induce a change in axillary staging and treatment?. (October 2020) Authors: Colier, E.; Pessers, S.; Vos, R.; Smidt, M.; van Roozendaal, L. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Impact of lymphedema on health-related quality of life in early-stage breast cancer patients treated breast conserving therapy with or without sentinel lymph node biopsy: 2-year results from the randomized controlled trial BOOG2013–08. (November 2022) Authors: Wintraecken, V.; Colier, E.; van Roozendaal, L.M.; Tjan-Heijnen, V.C.G.; Simons, J.M.; Strobbe, L.J.A.; van Maaren, M.C.; Boersma, L.J.; Lobbes, M.B.I.; van Dalen, T.; Linn, S.C.; Poortmans, P.M.P.; de Vries, J.; van Kuijk, S.M.J.; de Wilt, J.; Smidt, M.L. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The gene expression profile in clinically node negative T1–2 breast cancer patients: Its additional value in case of sentinel lymph node biopsy is not performed. (October 2020) Authors: Colier, E.; Vane, M.; Roozendaal, L.; de Boer, M.; Siesling, S.; Smidt, M. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗